Transfusion-associated GVHD: 10 years' experience at the American University of Beirut-Medical Center

Transfusion. 2003 Dec;43(12):1672-6. doi: 10.1046/j.0041-1132.2003.00578.x.

Abstract

Background: Although rare, transfusion-associated GVHD (TA-GVHD) is a fatal complication of blood transfusion in which active lymphocytes from the donor attack and destroy recipient organs and tissues.

Study design and methods: A search of patient records was carried out at the American University of Beirut-Medical Center, looking for patients who developed TA-GVHD over a 10-year period extending from 1991 to 2001. Relevant information was collected and analyzed.

Results: A total of 10 records were found as a result of this search. All were immunocompetent and received fresh nonleukoreduced, nonirradiated blood. The majority received the transfusion at outside periphery hospitals. They received different treatment modalities. The mortality rate was 100 percent.

Conclusion: TA-GVHD is a serious complication with very high mortality. Effective prevention guidelines should be established in Lebanon including irradiation and the creation of a central blood bank.

MeSH terms

  • Adult
  • Aged
  • Antilymphocyte Serum / therapeutic use
  • Cyclosporine / therapeutic use
  • Female
  • Graft vs Host Disease / diagnosis
  • Graft vs Host Disease / drug therapy
  • Graft vs Host Disease / etiology*
  • Graft vs Host Disease / mortality*
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Infant
  • Male
  • Medical Records
  • Middle Aged
  • Muromonab-CD3 / therapeutic use
  • Steroids / therapeutic use
  • Transfusion Reaction*

Substances

  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • Muromonab-CD3
  • Steroids
  • Granulocyte Colony-Stimulating Factor
  • Cyclosporine